Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (883)	4/9/1998 10:35:00 PM
From: Harold Lehman	Read Replies (2) \| Respond to of 1501

Regarding the tb test kit, I just found out one of the reasons it's taken so damn long to develop it. I'm not sure how few or how many people at Inflazyme knew this while it was happening, but there was a regulatory delay in getting the cell cultures into the U.K. to produce the monoclonal antibody needed for the test. It apparently took some fair amount of time, although I couldn't find out how much time, due to required protocols in testing their microbes as a potential health hazard. From what I can tell those involved did not tell their investor relations people, and we all know they sure as hell didn't tell us. I hope the new CEO will bring a lot more transparency and forthrightness in his representations to shareholders, large and small. If it doesn't interfere with negociations or other aspects of the company's operations we deserve to know what's going on. Enhancing shareholder value includes openness and transparency, hallmarks of a nonbackroom committment to those who have shown some faith. Another thing. On January 6, the tb project manager at Cortecs told me that there would be a press release in a few weeks to a few months from that time. All I know now reg. that is that IZP was supposed to get the hospital based test kits no later than by the end of March in order to coordinate Canadian testing (also, this testing takes much less time than for a therapeutic). But now they're supposed to receive it in April. Inflazyme is obviously not the only company making mistakes with time estimates. Also, I was told by that project manager that they didn't need any further approval for some countries as prior work was sufficient to show effectiveness of the test reagents. All they had to do was follow standard quality assurance protocols. He said that they wanted to test specificity of tb strains in different locales, and perhaps add another monoclonal in some areas if needed. I don't know how long this takes them to do. I agree with Sean that the successful launch of the tb test could bring in a ton of revenue. This is a much better test than today's gold standard, the skin test. Its ease of usage, as well as a worldwide increase in the incidence of tb, should create greater demand. When this test will finally be ready to go to market I don't know, but unless there's something that I just don't see, that should be a big day for Inflazyme. By the way Chuca, do you consider this to be spin?